Gauss

Recombinant Human PD-1 (CD279)-Fc Chimera (carrier-free) 10 µg

Réf. UGAP : 3689573 Réf. Fournisseur : 785102 Réf. Constructeur : 785102
Recombinant Human PD-1 (CD279)-Fc Chimera (carrier-free) 10 µg
Recombinant Human PD-1 (CD279)-Fc Chimera (carrier-free) 10 µg
Franco de port et d'emballage pour toutes les commandes supérieures à 80€ HT.

Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
La quantité choisie doit être comprise entre 1 et 999 999.
Il ne reste que 0 exemplaires.

Points clés

Programmed death-1 (PD-1) is a type I transmembrane protein initially isolated from apoptosis-induced cells by subtractive hybridization. The amino acid sequence of mouse PD-1 shares 59.4% identity to the human counterpart, and a putative tyrosine kinase-association motif is well conserved. Its extracellular region consists of a single Ig-like variable (IgV) domain. PD-1 is an inhibitory molecule expressed by activated B and T cells and has been implicated in immune tolerance. PD-L1 and PD-L2 are the ligands for PD-1 and their binding leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion. PD-1/PD-L1 interaction suppresses immune responses against autoantigens and tumors, and plays an important role in the maintenance of peripheral immune tolerance. Interaction between PD-1 and PD-L1 promote tolerance by blocking TCR-mediated signaling. PD-L1 expression by tumor cells allow tumor progression by suppressing antitumor T-cell responses. Antibodies against PD-1 or PD-L1 lead to increased antitumor immunity.;

En savoir plus

Garantie

Garantie 0 Mois

Description

Programmed death-1 (PD-1) is a type I transmembrane protein initially isolated from apoptosis-induced cells by subtractive hybridization. The amino acid sequence of mouse PD-1 shares 59.4% identity to the human counterpart, and a putative tyrosine kinase-association motif is well conserved. Its extracellular region consists of a single Ig-like variable (IgV) domain. PD-1 is an inhibitory molecule expressed by activated B and T cells and has been implicated in immune tolerance. PD-L1 and PD-L2 are the ligands for PD-1 and their binding leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion. PD-1/PD-L1 interaction suppresses immune responses against autoantigens and tumors, and plays an important role in the maintenance of peripheral immune tolerance. Interaction between PD-1 and PD-L1 promote tolerance by blocking TCR-mediated signaling. PD-L1 expression by tumor cells allow tumor progression by suppressing antitumor T-cell responses. Antibodies against PD-1 or PD-L1 lead to increased antitumor immunity.;

Caractéristiques

Fournisseur
BioLegend Europe BV
Marque
BIOLEGEND
Référence fabricant
785102
Référence distributeur
785102
Vendu par
10 μg
Quantité
N/A
Lieu de fabrication
USA
Lieu de stockage
Pays-Bas ou USA
Référence fabriquant similaire
785106
Soumis à carboglace
non
Classement dans le catalogue fournisseur
Recombinant Protein
Certification
RUO
Type d’application
bioassay
Type de produit
Recombinant Protein
Température de conservation (°C)
-20 ou -70 °C
Température de transport
Blue Ice
Organisme cible
Human
Source biologique
293E cells
Seuil de coupure des masses moléculaires MWCO
The 382 amino acid recombinant protein has a predicted molecular mass of approximately 42.8 kD. The DTT-reduced protein migrates at approximately 60 - 70 kD and and non-reduced protein migrates at approximately 100 - 120 kD by SDS-PAGE. Da
Concentration
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration, please enter the lot number in our online tools.
Pureté
>95%, as determined by Coomassie stained SDS-PAGE. %
Matière dangereuse
Non
Code douanier
38220000
Classement NCBI
5133
Nomenclature Nacres
NA.77
Nomenclature CEA
SGP01
Nomenclature IRSN
273
Nomenclature INSERM
NA.NA77
Nomenclature CNRS
NA77
Nomenclature CHU
18.551
Nomenclature DGOS
LD11AOOO
Reprise en cas d’erreur client
non